Prestige Consumer Healthcare (NYSE:PBH) Sets New 52-Week High – What’s Next?

Prestige Consumer Healthcare Inc. (NYSE:PBH)’s stock price reached a new 52-week high on Wednesday . The stock traded as high as $79.25 and last traded at $78.62, with a volume of 5505 shares traded. The stock had previously closed at $74.77.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Jefferies Financial Group restated a “hold” rating and issued a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. DA Davidson increased their price target on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of “Moderate Buy” and an average price target of $94.20.

Prestige Consumer Healthcare Stock Up 3.8 %

The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.90 and a current ratio of 3.23. The company has a market cap of $3.85 billion, a price-to-earnings ratio of 18.98, a price-to-earnings-growth ratio of 2.08 and a beta of 0.47. The business has a 50-day simple moving average of $72.24 and a 200-day simple moving average of $69.65.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.86 by $0.04. The business had revenue of $267.10 million during the quarter, compared to the consensus estimate of $260.54 million. Prestige Consumer Healthcare had a return on equity of 12.55% and a net margin of 18.43%. During the same period in the prior year, the company earned $1.06 earnings per share. The company’s revenue was down 4.4% compared to the same quarter last year. On average, equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.43 earnings per share for the current fiscal year.

Institutional Trading of Prestige Consumer Healthcare

Hedge funds have recently added to or reduced their stakes in the business. Covestor Ltd boosted its position in shares of Prestige Consumer Healthcare by 21.6% in the first quarter. Covestor Ltd now owns 834 shares of the company’s stock worth $61,000 after buying an additional 148 shares during the period. Evergreen Capital Management LLC boosted its stake in Prestige Consumer Healthcare by 5.4% in the second quarter. Evergreen Capital Management LLC now owns 3,143 shares of the company’s stock valued at $216,000 after acquiring an additional 160 shares during the period. Miller Howard Investments Inc. NY grew its position in shares of Prestige Consumer Healthcare by 2.2% during the second quarter. Miller Howard Investments Inc. NY now owns 7,762 shares of the company’s stock worth $534,000 after acquiring an additional 165 shares during the last quarter. OLD National Bancorp IN increased its stake in shares of Prestige Consumer Healthcare by 4.4% in the third quarter. OLD National Bancorp IN now owns 3,974 shares of the company’s stock valued at $287,000 after purchasing an additional 168 shares during the period. Finally, Huntington National Bank increased its position in Prestige Consumer Healthcare by 39.9% in the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after acquiring an additional 181 shares during the period. 99.95% of the stock is owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.